Source comparison
Receptor Mechanisms: GHRP-2 Acetate vs Tesamorelin Which Better Comparison
GHRP-2 acetate (growth hormone-releasing peptide-2) operates as a ghrelin receptor agonist, binding GHS-R1a receptors distributed across the hypothalamus, pituitary, hippocampus, and gastrointestinal tract. That receptor promiscuity explains the peptide's broa
This comparison does not assign a generated winner or score.
- GHRP-2 acetate (growth hormone-releasing peptide-2) operates as a ghrelin receptor agonist, binding GHS-R1a receptors distributed across the hypothalamus, pituitary, hippocampus, and gastrointestinal tract. That receptor promiscuity explains the peptide's broad systemic effects: GH secretion peaks 30–45 minutes post-administration, accompanied by transient cortisol elevation (typically 20–40% above baseline) and modest prolactin increases. The ghrelin pathway's role in appetite regulation means GHRP-2 can stimulate hunger in some research models. A downstream effect that complicates metabolic studies focused purely on lipolysis.
- Tesamorelin, by contrast, is a stabilised analogue of human GHRH with 44 amino acids and a trans-3-hexenoic acid modification at the N-terminus. It binds exclusively to GHRH receptors on somatotroph cells in the anterior pituitary, triggering cyclic AMP (cAMP) accumulation and subsequent GH release without activating ghrelin-mediated hunger or stress hormone pathways. The FDA-approved dosing for tesamorelin in HIV-associated lipodystrophy is 2mg subcutaneously daily. A protocol that consistently reduces visceral adipose tissue (VAT) by 15–18% over 26 weeks without the cortisol spikes observed with ghrelin agonists. Research from Massachusetts General Hospital demonstrated that tesamorelin's VAT reduction occurs independently of changes in subcutaneous fat, suggesting receptor-specific lipolytic signalling in visceral adipocytes.
- GHRP-2 acetate shows greater versatility across anabolic endpoints: bone mineral density improvements, lean mass accrual, and enhanced recovery markers in athletic populations. The peptide's GH secretagogue activity operates synergistically when stacked with GHRH analogues. Combining GHRP-2 with CJC-1295 (a GHRH analogue) produces supra-additive GH release exceeding either compound alone. That synergy reflects complementary receptor activation: ghrelin pathway stimulation amplifies the magnitude of GH pulses initiated by GHRH receptor binding. Real Peptides' CJC1295 Ipamorelin 5MG 5MG leverages this exact principle. Pairing a GHRH analogue with a ghrelin agonist to maximise pulsatile GH output.